Genisphere and the Lankenau Institute for Medical Research (LIMR) will continue their colloboration on microRNA (miRNA) biomarker development for Ulcerative Colitis (UC) and will expand the partnership to include Crohn's Disease and other inflammatory bowel disorders.
The aim of the partnership is to develop a diagnostic test to know how patients are being diagnosed in their respective disease and also to identify how they are responding to the treatment.
The organisations will use the Affymetrix GeneChip miRNA Array in the identification of the miRNA biomarker panels and to develop new tools in assisting the clinicians in diagnosing and treating the disorders.
LIMR president and CEO George Prendergast said, "we see an opportunity through this collaboration to provide clinicians with a tool that helps them rapidly and specifically identify the patient's condition so that care can be targeted the best."
Genisphere chief science officer Bob Getts said the partnership wants to identify biomarker panels that can classify the various forms of IBD.
"From this we can develop a tool that will help to rapidly and accurately identify the patient's condition so personalized treatment may be administered as soon as possible,'' Getts added.
